Waters Co. (NYSE:WAT) Shares Bought by Cwm LLC

Cwm LLC lifted its position in Waters Co. (NYSE:WAT) by 7.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 995 shares of the medical instruments supplier’s stock after acquiring an additional 72 shares during the quarter. Cwm LLC’s holdings in Waters were worth $343,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in WAT. Exchange Traded Concepts LLC acquired a new position in Waters during the 4th quarter valued at approximately $35,000. Wetzel Investment Advisors Inc. acquired a new position in Waters during the 4th quarter valued at approximately $39,000. Turtle Creek Wealth Advisors LLC acquired a new position in Waters during the 4th quarter valued at approximately $41,000. VisionPoint Advisory Group LLC boosted its position in Waters by 300.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 108 shares during the period. Finally, Livforsakringsbolaget Skandia Omsesidigt boosted its position in Waters by 186.3% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 146 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 95 shares during the period. Institutional investors and hedge funds own 94.01% of the company’s stock.

Insider Transactions at Waters

In other news, Director Christopher A. Kuebler sold 4,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $361.64, for a total transaction of $1,446,560.00. Following the sale, the director now directly owns 14,716 shares of the company’s stock, valued at $5,321,894.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Richard H. Fearon bought 1,000 shares of the business’s stock in a transaction dated Tuesday, May 28th. The shares were bought at an average cost of $332.90 per share, with a total value of $332,900.00. Following the completion of the transaction, the director now directly owns 1,653 shares of the company’s stock, valued at $550,283.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Christopher A. Kuebler sold 4,000 shares of the business’s stock in a transaction on Wednesday, May 15th. The stock was sold at an average price of $361.64, for a total value of $1,446,560.00. Following the sale, the director now directly owns 14,716 shares in the company, valued at $5,321,894.24. The disclosure for this sale can be found here. Company insiders own 0.82% of the company’s stock.

Waters Stock Up 0.1 %

WAT opened at $290.27 on Friday. Waters Co. has a one year low of $231.90 and a one year high of $367.21. The company has a debt-to-equity ratio of 1.60, a quick ratio of 1.30 and a current ratio of 1.94. The stock’s fifty day moving average is $318.28 and its 200-day moving average is $324.22. The company has a market capitalization of $17.22 billion, a PE ratio of 28.49, a P/E/G ratio of 4.62 and a beta of 0.97.

Waters (NYSE:WAT) last posted its quarterly earnings data on Tuesday, May 7th. The medical instruments supplier reported $2.21 EPS for the quarter, topping analysts’ consensus estimates of $2.10 by $0.11. Waters had a return on equity of 66.59% and a net margin of 20.75%. The company had revenue of $636.80 million for the quarter, compared to the consensus estimate of $635.57 million. During the same quarter in the previous year, the business earned $2.49 EPS. The company’s quarterly revenue was down 7.0% compared to the same quarter last year. On average, equities analysts predict that Waters Co. will post 11.85 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on WAT. Jefferies Financial Group began coverage on Waters in a research report on Monday, June 3rd. They set a “hold” rating and a $320.00 price objective for the company. Barclays reduced their price objective on Waters from $300.00 to $295.00 and set an “underweight” rating for the company in a research report on Wednesday, May 8th. Robert W. Baird cut their target price on Waters from $319.00 to $312.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. Stifel Nicolaus lifted their target price on Waters from $330.00 to $332.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. Finally, TD Cowen lifted their target price on Waters from $350.00 to $358.00 and gave the company a “hold” rating in a research note on Wednesday, May 8th. One investment analyst has rated the stock with a sell rating and eleven have issued a hold rating to the stock. According to MarketBeat.com, Waters currently has a consensus rating of “Hold” and a consensus target price of $307.20.

Waters Profile

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.